Johnson & Johnson has announced the acquisition of Proteologix, a privately-held biotech company specializing in bispecific antibodies for immune diseases, for $850 million, with a potential additional milestone payment.

Proteologix has two bispecific antibodies in development: PX128, targeting IL-13 and TSLP, for moderate-to-severe atopic dermatitis (AD) and asthma, ready for Phase 1, and PX130, targeting IL-13 and IL-22, in preclinical development for moderate-to-severe AD.

The acquisition also includes other bispecific antibody programs for various diseases, strengthening J&J's capabilities in immune therapies.

'Integrating Proteologix's bispecific antibodies into our pipeline is an important first step in delivering on our commitment to people living with AD', said Candice Long, Global Vice President, Immunology, Johnson & Johnson.


Copyright (c) 2024 CercleFinance.com. All rights reserved.